Ampyra® two-year safety data presented at ECTRIMS

Dalfampridine, or Ampyra, is a potassium channel blocker that is shown to improve visual function, motor skills and relieve fatigue in MS patients.

Ampyra® two-year safety data presented at ECTRIMS

Postby MSUK » Wed Oct 10, 2012 12:14 pm

Image

Acorda Therapeutics, Inc. today announced safety data from more than 62,400 people with multiple sclerosis (MS) taking Ampyra (dalfampridine) Extended Release Tablets, 10 mg during the first two years of availability in the United States. The data showed that the safety profile of Ampyra is similar to that observed in clinical trials.

This analysis was presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held in Lyon, France from October 10-13. Ampyra is known as prolonged-, modified, or sustained-release fampridine (Fampyra®) in some countries outside the United States.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2092
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Ampyra

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users